Osivax and GC Biopharma announced a strategic collaboration to develop a new-generation influenza vaccine. The vaccine will combine OVX836 and GC FLU. Osivax gained the rights to advance a combined shot.
Older adults face four vaccine decisions this fall, while the federal schedule still carries a 2025 date. Flu and pneumonia deaths have fallen for 25 years, but one American age group saw an increase.